Article Text

Download PDFPDF
Original article
Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma
  1. Yan-Yi Jiang1,
  2. De-Chen Lin1,2,
  3. Anand Mayakonda1,
  4. Masaharu Hazawa1,
  5. Ling-Wen Ding1,
  6. Wen-Wen Chien1,
  7. Liang Xu1,
  8. Ye Chen1,
  9. Jin-Fen Xiao1,
  10. William Senapedis3,
  11. Erkan Baloglu3,
  12. Deepika Kanojia1,
  13. Li Shang4,
  14. Xin Xu4,
  15. Henry Yang1,
  16. Jeffrey W Tyner5,
  17. Ming-Rong Wang4,
  18. H Phillip Koeffler1,6,7
  1. 1 Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
  2. 2 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
  3. 3 Department of Drug Discovery, Karyopharm Therapeutics Inc., Newton, Massachusetts, USA
  4. 4 State Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
  5. 5 Department of Cell, Developmental & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA
  6. 6 Division of Hematology/Oncology, Cedars-Sinai Medical Center, University of California, Los Angeles School of Medicine, Los Angeles, California, USA
  7. 7 National University Cancer Institute, National University Health System and National University of Singapore, Singapore, Singapore
  1. Correspondence to Dr Yan-Yi Jiang, Cancer Science Institute of Singapore, National University of Singapore, NUS, CSI, MD6 14 Medical drive #13-01, Singapore 119260, Singapore; jyy.36000{at} Dr De-chen Lin, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China; dchlin11{at} Dr Ming-Rong Wang, Cancer Institute/Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100021, China; wangmr2015{at}


Objectives Oesophageal squamous cell carcinoma (OSCC) is an aggressive malignancy and the major histological subtype of oesophageal cancer. Although recent large-scale genomic analysis has improved the description of the genetic abnormalities of OSCC, few targetable genomic lesions have been identified, and no molecular therapy is available. This study aims to identify druggable candidates in this tumour.

Design High-throughput small-molecule inhibitor screening was performed to identify potent anti-OSCC compounds. Whole-transcriptome sequencing (RNA-Seq) and chromatin immunoprecipitation sequencing (ChIP-Seq) were conducted to decipher the mechanisms of action of CDK7 inhibition in OSCC. A variety of in vitro and in vivo cellular assays were performed to determine the effects of candidate genes on OSCC malignant phenotypes.

Results The unbiased high-throughput small-molecule inhibitor screening led us to discover a highly potent anti-OSCC compound, THZ1, a specific CDK7 inhibitor. RNA-Seq revealed that low-dose THZ1 treatment caused selective inhibition of a number of oncogenic transcripts. Notably, further characterisation of the genomic features of these THZ1-sensitive transcripts demonstrated that they were frequently associated with super-enhancer (SE). Moreover, SE analysis alone uncovered many OSCC lineage-specific master regulators. Finally, integrative analysis of both THZ1-sensitive and SE-associated transcripts identified a number of novel OSCC oncogenes, including PAK4, RUNX1, DNAJB1, SREBF2 and YAP1, with PAK4 being a potential druggable kinase.

Conclusions Our integrative approaches led to a catalogue of SE-associated master regulators and oncogenic transcripts, which may significantly promote both the understanding of OSCC biology and the development of more innovative therapies.


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.